Separately, Celgene and bluebird bio to col­lab­o­rate with the Center for Cell and Gene Therapy to ad­vance new and existing CAR T-cell pro­grams

Cambridge, MA (Press Release) – bluebird bio, a privately-held bio­technology com­pany focused on gene ther­apy, today announced the for­ma­tion of a broad, global strategic col­lab­o­ra­tion with Celgene Corpo­ra­tion to discover, develop and com­mer­cial­ize novel disease-altering gene ther­a­pies in on­col­ogy. The col­lab­o­ra­tion will focus on applying gene ther­apy tech­nology to genetically modify a patient’s own T-cells, known as chi­meric an­ti­gen re­cep­tor (CAR) T-cells, to target and destroy cancer cells. The multi-year research and devel­op­ment col­lab­o­ra­tion has the poten­tial to lead to the devel­op­ment and com­mer­cial­iza­tion of multiple CAR T-cell prod­ucts. Celgene has an option …

Compound in Development for Multiple Myeloma

Horsham, PA (Press Release) – Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharma­ceu­tical Com­panies of Johnson & Johnson, announced today that it has executed a global license and devel­op­ment agree­ment with the Danish com­pany Genmab A/S for the anti-cancer com­­pound, dara­tu­mu­mab. Dara­tu­mu­mab (HuMax®-CD38) is a human CD38 mono­clonal anti­body cur­rently in Phase I/II studies in re­lapsed, refractory multiple myeloma.

"Janssen was one of the first com­pa­nies to recog­nize the power and promise of mono­clonal anti­bodies and today is a world leader in biologics. We look for­ward to applying that same …

Company Has Also Requested Scientific Advice on its Phase 3 Program with Perifosine in Refractory Advanced Colorectal Cancer.

Quebec City, QC (Press Release) – Æterna Zentaris Inc. (NASDAQ: AEZS,TSX: AEZ) (the "Company"), a late-stage drug devel­op­ment com­pany specialized in on­col­ogy and en­do­crine ther­apy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently ini­ti­ated Phase 3 pro­grams for the devel­op­ment of its lead anticancer com­pound, perifosine, in its two lead indi­ca­tions, multiple myeloma and refractory ad­vanced colorectal cancer. Previously, agree­ment was reached with the U.S. Food and Drug Admin­istra­tion (FDA) on a Special Protocol Assessment (SPA) for the pivotal …